Novartis received approval for a one-time treatment for a rare childhood muscle-wasting disease called spinal muscular atrophy. The price tag is expected to be $2.1 million per dose.
I asked myself, why are there favorite diseases and those that aren’t so favored by medicine, media and mankind?
Why can’t we take a percentage of what we spend for diabetes, heart disease and cancer and spend it on mental illness, addiction or low-incidence diseases?
How do you set a price for a cure, when five illnesses might benefit more from the same investment? Who makes these decisions?
– Edward Stevens, Stevens Strategic Communications